{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:43:46Z","timestamp":1790225026292,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.drugalcdep.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T01:44:58Z","timestamp":1466214298000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)"],"prefix":"10.1016","volume":"165","author":[{"given":"Howard D.","family":"Chilcoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Coplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.02.006","article-title":"Development and impact of prescription opioid abuse deterrent formulation technologies","volume":"138","author":"Alexander","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2165\/11635860-000000000-00000","article-title":"Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?","volume":"72","author":"Bannwarth","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3109\/10826084.2013.866963","article-title":"Does the new formulation of OxyContin\u00ae deter misuse? A qualitative analysis","volume":"49","author":"Buer","year":"2014","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7517-8-29","article-title":"Abuse risks and routes of administration of different prescription opioid compounds and formulations","volume":"8","author":"Butler","year":"2011","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5055\/jom.2012.0128","article-title":"Characteristics of prescribers whose patients shop for opioids: results from a cohort study","volume":"8","author":"Cepeda","year":"2012","journal-title":"J. Opioid. Manag."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0091270012436561","article-title":"Opioid shopping behavior: how often, how soon, which drugs, and what payment method","volume":"53","author":"Cepeda","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc1204141","article-title":"Effect of abuse-deterrent formulation of OxyContin","volume":"367","author":"Cicero","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0050","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.pain.2013.07.025","article-title":"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States","volume":"154","author":"Cicero","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0055","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.3522","article-title":"Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics","volume":"22","author":"Coplan","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/add.12746","article-title":"Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol","volume":"110","author":"Degenhardt","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0070","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0075","first-page":"68","article-title":"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users","volume":"544","author":"Harris","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2014.02.018","article-title":"The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers","volume":"139","author":"Havens","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0085","unstructured":"IMS Institute for Healthcare Informatics, 2012. The Use of Medicines in the United States: Review of 2011. Parsippany, NJ."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/17425247.2013.751095","article-title":"Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?","volume":"10","author":"Lourenco","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugalcdep.2009.01.019","article-title":"Pathways between nonmedical opioid use\/dependence and psychiatric disorders: results from the National Epidemiologic Survey on alcohol and related conditions","volume":"103","author":"Martins","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0100","doi-asserted-by":"crossref","first-page":"e69241","DOI":"10.1371\/journal.pone.0069241","article-title":"Estimating the prevalence of opioid diversion by doctor shoppers in the United States","volume":"8","author":"McDonald","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0105","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1001\/jama.2008.793","article-title":"Prescription opioids, overdose deaths, and physician responsibility","volume":"300","author":"McLellan","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0110","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1185\/03007995.2014.915803","article-title":"Use of prescription opioids with abuse-deterrent technology to address opioid abuse","volume":"30","author":"Michna","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/papr.12093","article-title":"Abuse-deterrent formulations of opioid analgesics","volume":"14","author":"Pergolizzi","year":"2014","journal-title":"Pain Pract."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-013-0085-x","article-title":"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(\u00ae) tablets compared with original OxyContin (\u00ae) tablets in healthy adults","volume":"33","author":"Perrino","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0125","unstructured":"Researched Abuse, Diversion, and Addiction-Related Surveillance System (RADARS), 2013. Abuse Deterrent Formulations\u2014Updated RADARS System Data. RADARS System. Third Quarter Newsletter. 8,1."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/pds.3658","article-title":"Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation","volume":"23","author":"Sessler","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0135","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jpain.2013.04.011","article-title":"Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010","volume":"14","author":"Severtson","year":"2013","journal-title":"J. Pain."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/009885881404000103","article-title":"Combating the prescription painkiller epidemic: a national prescription drug reporting program","volume":"40","author":"Shepherd","year":"2014","journal-title":"Am. J. Law Med."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.drugalcdep.2010.05.007","article-title":"Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics","volume":"112","author":"Wilsey","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.009_bib0150","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pds.2129","article-title":"An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program","volume":"20","author":"Wilsey","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616301557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616301557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T01:29:56Z","timestamp":1536629396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871616301557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":30,"alternative-id":["S0376871616301557"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.06.009","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}